Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Stoten will be taking over from retiring Managing Director Linda Naylor from April.

Oxford University Innovation (OUI), the research commercialisation company of Oxford University, has named its new Chief Operating Officer (COO). Dr Adam Stoten, the current Head of Technology Transfer Life Sciences at OUI, will be taking up the newly-created position from 1st April 2017.

Stoten, who holds a PhD in Immunology from the University of Nottingham, has been a leading figure at OUI since 2005 when he joined the company as a Project Manager. In 2010, he joined the Oxford-Emergent Tuberculosis Consortium, a joint venture between Oxford University and Emergent BioSolutions, which conducted the first ever efficacy study of a new tuberculosis vaccine in infants. He remained with the spinout until 2013 as its Deputy General Manager, before returning to OUI to head up its life sciences commercialisation activities.

Read more (Oxford University Innovation website)

Similar stories

AIMday in Women's Health - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Professor Trish Greenhalgh Highly Commended in the O²RB Excellence in Impact Awards 2021

Congratulations to Professor Trish Greenhalgh (Nuffield Department of Primary Care Health Sciences) who has been Highly Commended in the O²RB Excellence in Impact Awards 2021.

Turing Fellowships for over 30 Oxford academics

Thirty-three University of Oxford researchers have been named Turing Fellows for the 2021/22 academic year, including eight from the Medical Sciences Division.